Predictability of peripheral lymphocyte reduction of novel S1P1 agonists by in vitro GPCR signaling profile

Journal of Biomolecular Screening

Volumn 18, Issue 9, 2013, Pages 997-1007

  Xu, Han ^a   McElvain, Michele ^a   Fiorino, Mike ^a   Henkle, Brad ^a,b   Sherman, Lisa ^a   Xu, Yang ^a   Tominey, Elizabeth ^b,c   Kelley, Keith ^a   Adlam, Matt ^a   Bürli, Roland ^a,d   Siu, Jerry ^a,e   Wong, Min ^a   Cee, Victor J ^a  

^a AMGEN INC   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c Pain Care Physicians   (United States)

^d MEDIMMUNE   (United States)

^e NOVO NORDISK A S   (Denmark)

Author keywords

arrestin; G protein coupling; S1P1

Indexed keywords

5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; ADENYLATE CYCLASE; BETA ARRESTIN; BIOGENIC AMINE; CALCIUM; CYCLIC AMP; FTY 720P; FTY 750P; G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; CALCIUM MOBILIZATION; ENANTIOMER; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; PERIPHERAL LYMPHOCYTE; PREDICTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEREOCHEMISTRY;

G-PROTEIN COUPLING; S1P1; Β-ARRESTIN;

ADENYLATE CYCLASE; ARRESTINS; BIOLOGICAL ASSAY; CALCIUM; DRUG DISCOVERY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; HUMANS; KINETICS; LYMPHOCYTE DEPLETION; ORGANOPHOSPHATES; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROTEIN CONFORMATION; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; SPHINGOSINE;

EID: 84884661843     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057113488629     Document Type: Article

References (35)

1. Bohinc B. N., Gesty-Palmer D.. β-Arrestin-Biased Agonism at the Parathyroid Hormone Receptor Uncouples Bone Formation from Bone Resorption. Endocr. Metab. Immune Disord. Drug Targets. 2011 ; 11: 112-119
2. Breit A., Büch T. R., Boekhoff I., et al. Alternative G Protein Coupling and Biased Agonism: New Insights into Melanocortin-4 Receptor Signalling. Mol. Cell. Endocrinol. 2011 ; 331: 232-240
3. Means C. K., Miyamoto S., Chun J., et al. S1P1 Receptor Localization Confers Selectivity for Gi-Mediated cAMP and Contractile Responses. J. Biol. Chem. 2008 ; 283: 11954-11963
4. Marsolais D., Rosen H.. Chemical Modulators of Sphingosine-1-Phosphate Receptors as Barrier-Oriented Therapeutic Molecules. Nat. Rev. Drug Discov. 2009 ; 8: 297-307
5. Brinkmann V., Cyster J. G., Hla T.. FTY720: Sphingosine 1-Phosphate Receptor-1 in the Control of Lymphocyte Egress and Endothelial Barrier Function. Am. J. Transplant. 2004 ; 4: 1019-1027
6. Yatomi Y., Ruan F., Hakomori S., et al. Sphingosine-1-Phosphate: A Platelet-Activating Sphingolipid Released from Agonist-Stimulated Human Platelets. Blood. 1995 ; 86: 193-202
7. Venkataraman K., Lee Y. M., Michaud J., et al. Vascular Endothelium as a Contributor of Plasma Sphingosine 1-Phosphate. Circ. Res. 2008 ; 102: 669-676 (Pubitemid 351457860)
8. Pappu R., Schwab S. R., Cornelissen I., et al. Promotion of Lymphocyte Egress into Blood and Lymph by Distinct Sources of Sphingosine-1-Phosphate. Science. 2007 ; 316: 295-298 (Pubitemid 46633109)
9. Rosen H., Gonzalez-Cabrera P. J., Sanna M. G., et al. Sphingosine 1-Phosphate Receptor Signaling. Annu. Rev. Biochem. 2009 ; 78: 743
10. LevKau B.. Sphingosine-1-Phosphate in the Regulation of Vascular Tone. Circ. Res. 2008 ; 103: 231-233
11. Sanna M. G., Liao J., Jo E., et al. Sphingosine-1 Phosphate (S1P) Receptor Subtypes S1P1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate. J. Biol. Chem. 2004 ; 279: 13839-13848 (Pubitemid 38468916)
12. Roviezzo F., Di Lorenzo A., Bucci M., et al. Sphingosine-1-Phosphate/ Sphingaine Kinase Pathway Is Involved in Mouse Airway Hyperresponsiveness. Am. J. Respir. Cell Mol. Biol. 2007 ; 36: 757-762 (Pubitemid 46871431)
13. Kono M., Belyantseva I. A., Skoura A., et al. Deafness and Stria Vascularis Defects in S1P2 Receptor-Null Mice. J. Biol. Chem. 2007 ; 282: 10690-10696 (Pubitemid 47093459)
14. Mandala S. M., Hajdu R., Bergstrom J., et al. Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists. Science. 2002 ; 296: 346-350
15. van Brocklyn J. R., Lee M. J., Menzeleev R., et al. Dual actions of Sphingosine-1-Phosphate: Extracellular through the Gi-Coupled Receptor Edg-1 and Intracellular to Regulate Proliferation and Survival. J. Cell Biol. 1998 ; 142: 229-240 (Pubitemid 28341153)
16. Spiegel S., Milstien S.. Sphingosine-1-Phosphate: An Enigmatic Signalling Lipid. Nat. Rev. Mol. Cell Biol. 2003 ; 4: 397-407 (Pubitemid 36565571)
17. Matsuura M., Imayoshi T., Okumoto T.. Effect of FTY720, a Novel Immunosuppressant, on Adjuvant- and Collagen-Induced Arthritis in Rats. Int. J. Immunopharmacol. 2000 ; 22: 323-331 (Pubitemid 30109509)
18. Kappos L., Antel J., Comi G., et al. Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis. N. Engl. J. Med. 2006 ; 355: 1124
19. Brinkmann V.. FTY720 (Fingolimod) in Multiple Sclerosis: Therapeutic Effect in the Immune and the Central Nervous System. Br. J. Pharmacol. 2009 ; 158: 1173-1182
20. Shimizu H., Takahashi M., Kaneko T.. KRP-203, a Novel Synthetic Immunosuppressant, Prolongs Graft Survival and Attenuates Chronic Rejection in Rat Skin and Heart Allografts. Circulation. 2005 ; 111: 222
21. Saha A. K., Yu X., Lin J., et al. Benzofuran Derivatives as Potent, Orally Active S1P1 Receptor Agonists: A Preclinical Lead Molecule for MS. ACS Med. Chem. Lett. 2011 ; 2: 97-101
22. Rosen H., Sanna M. G., Cahalan S. M., et al. Tipping the Gatekeeper: S1P Regulation of Endothelial Barrier Function. Trends Immunol. 2007 ; 28: 102-107 (Pubitemid 46283694)
23. Jo E., Sanna M. G., Gonzalez-Cabrera P. J., et al. S1P1 Selective In-Vivo Active Agonist from High Throughput Screening: Off the Shelf Chemical Probes of Receptor Interactions, Signaling and Fate. Chem. Biol. 2005 ; 12: 703
24. van der Lee M. M. C., Bras M., van Koppen J. C., et al. Beta-Arrestin Recruitment Assay for the Identification of Agonists of the S1P Receptor EDG-1. J. Biomol. Screen. 2008 ; 13: 986
25. Cee V. J., Frohn M., Lanman B. A., et al. Discovery of AMG 369, a Thiazolo[5,4-b]pyridine Agonist of S1P1 and S1P5. ACS Med. Chem. Lett. 2011 ; 2: 107-112
26. Lanman B. A., Cee V. J., Cheruku S. R., et al. Discovery of a Potent, S1P(3)-Sparing Benzothiazole Agonist of Sphingosine-1-Phosphate Receptor 1 (S1P(1)). ACS Med. Chem. Lett. 2011 ; 2: 102-106
27. Pennington L. D., Sham K. K. C., Pickrell A. J., et al. 4-Methoxy-N-[2-(trifluoromethyl)biphenyl-4-ylcarbamoyl]nicotinamide: A Potent and Selective Agonist of S1P1. ACS Med. Chem. Lett. 2011 ; 2: 752-757
28. Frohn M., Cee V. J., Lanman B. A., et al. Novel 5- and 6-Substituted Benzothiazoles with Improved Physicochemical Properties: Potent S1P1 Agonists with In Vivo Lymphocyte-Depleting Activity. Bioorg. Med. Chem. Lett. 2012 ; 22: 628-633
29. Harrington P. E., Croghan M. D., Fotsch C., et al. Optimization of a Potent, Orally Active S1P1 Agonist Containing a Quinolinone Core. ACS Med. Chem. Lett. 2012 ; 3: 74-78
30. Pennington L. D., Croghan M. D., Sham K. K., et al. Quinolinone-Based Agonists of S1P1: use of a N-scan SAR Strategy to Optimize In Vitro and In Vivo Activity. Bioorg. Med. Chem. Lett. 2012 ; 22: 527-531
31. Reed A. B., Lanman B. A., Neira S., et al. Isoform-Selective Thiazolo[5,4-b]pyridine S1P1 Agonists Possessing Acyclic Amino Carboxylate Head-Groups. Bioorg. Med. Chem. Lett. 2012 ; 22: 1779-1783
32. Hale J., Lynch C. L., Neway W., et al. A Rational Utilization of High-Throughput Screening Affords Selective, Orally Bioavailable 1-Benzyl-3-Carboxyazetidine Sphingosine-1-Phosphate-1 Receptor Agonists. J. Med. Chem. 2004 ; 47: 6662-6665 (Pubitemid 40053753)
33. Reiter E., Lefkowitz R. J.. GRKs and β-Arrestins: Roles in Receptor Silencing, Trafficking and Signaling. Trends Endocrinol. Metabol. 2006 ; 17: 159
34. Sensken S.-C., Stäubert C., Keul P., et al. Selective Activation of G alpha i Mediated Signalling of S1P3 by FTY720-Phosphate. Cell. Signal. 2008 ; 20: 1125
35. Kappos L., Radue E W., O'Connor P., et al. A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. N. Engl. J. Med. 2010 ; 362: 387-401